Last reviewed · How we verify
Noxiptilin (NOXIPTILINE)
Noxiptilin (generic name: NOXIPTILINE) is a drug. It is currently in Phase 2 development.
Noxiptilin works by binding to specific proteins or receptors in the body to produce a therapeutic effect.
Noxiptilin (NOXIPTILINE) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further information on its mechanism of action, safety considerations, and availability is not available. More research is needed to understand its potential uses and risks.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NOXIPTILINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and proteins or receptors are like keys. Noxiptilin is like a key that fits into a specific lock, allowing it to turn and unlock a particular cellular process. This process can help treat a variety of diseases, but more research is needed to understand exactly how it works.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Noxiptilin CI brief — competitive landscape report
- Noxiptilin updates RSS · CI watch RSS
Frequently asked questions about Noxiptilin
What is Noxiptilin?
How does Noxiptilin work?
What is the generic name of Noxiptilin?
What development phase is Noxiptilin in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing